health pharma news today obesity drugs glp-1 Drugmaker Eli Lilly announced that the FDA approved its daily pill, which will be marketed under the name Foundayo, to treat obesity. ABC News' Youri Benadjaoud reports Market Overview: GLP-1 Agonists and
Description
Trulicity lawsuits have largely been organized through a federal multidistrict litigation (MDL), not a traditional class action
was funded by an MRC Clinical Research Training Fellowship
more frequent at higher concentrations Diarrhea common during early exposure or escalation periods Constipation reported alongside other GI disturbances Increased heart rate average increase of roughly 2 to 3 beats per minute Administration site reactions ranging from mild redness to localized nodules Gallbladder disorders including gallstones, especially at higher concentrations and longer durations Acute kidney injury primarily linked to volume contraction from GI fluid loss Pancreatitis a labeled risk, though large meta-analyses show no significant increase vs
[DOI] [PubMed] [Google Scholar] 67.Lovshin JA, Barnie A, DeAlmeida A, Logan A, Zinman B, Drucker DJ
Berberine studies are generally smaller, of variable quality, and lack long-term safety data
